A new treatment option for adult and paediatric patients with a rare soft tissue cancer has been approved. The FDA has approved new immunotherapy drug atezolizumab (Tecentriq) for patients with advanced alveolar soft part sarcoma (ASPS) that has either spread to other parts of the body or cannot be removed by surgery for another reason.
Ook interessant voor je
FDA panel calls for improved pulse oximeters, highlighting racial disparity
Experts say pulse oximeters are less accurate when used on darker skin, prompting calls for improvements in the devices. Throughout the COVID-19 pandemic, pulse oximeters have been a common tool to measure blood oxygen...
25 x gelezen
European Commission approves potential new treatment for Pompe disease
The European Commission (EC) has issued a marketing authorisation for Sanofi Genzyme’s therapy Nexviadyme (avalglucosidase alfa) for the long-term treatment of both late-onset and infantile-onset Pompe disease. Pompe...
4 x gelezen
AbbVie submits migraine prevention drug to EMA for marketing authorisation
AbbVie has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for atogepant as a migraine treatment for adults who have at least four migraine days per month. Atogepant is an...
3 x gelezen